Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

about

Indel detection from RNA-seq data: tool evaluation and strategies for accurate detection of actionable mutations.Identification of candidate genes for lung cancer somatic mutation test kits.Indel sensitive and comprehensive variant/mutation detection from RNA sequencing data for precision medicine

P2860

Q36089979-FAE0C41D-FC6F-427C-9584-2E80E803B76A Q42665905-55794520-A921-427B-A21E-3FA92B232BE0 Q58739312-11A048A8-7979-4733-A619-CC917604592B

P2860

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

Item

http://www.wikidata.org/entity/Q35896601

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

@ast

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

@en

type

Item

label

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

@ast

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

@en

prefLabel

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

@ast

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

@en

P1476

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

@en

P2093

Thomas J Lynch

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

P304

1490-1492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-3282

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Katerina Politi

P577

2012-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22317760

http://www.w3.org/2001/XMLSchema#string

P932

3329215

http://www.w3.org/2001/XMLSchema#string

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

about

P2860

P2860

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932